Safety of an intravenous formulation of lamotrigine

Jeannine M Conway, Angela K Birnbaum, Ilo E Leppik, Page B. Pennell, James R. White, John O. Rarick, Rory P Remmel

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose Intravenous (IV) formulations are useful when treating patients where oral administration is not possible and to study certain pharmacokinetic parameters such as bioavailability. We developed a stable-labeled IV formulation of lamotrigine (LTG) for studying pharmacokinetics in epilepsy patients. Methods Stable-labeled IV LTG was given to 20 persons with epilepsy (6 men; 14 women) with a mean age of 34.8 years (SD 11.7). A 50 mg dose of LTG (stable labeled) was given intravenously and replaced 50 mg of the regular morning oral dose of LTG (unlabeled, commercially available formulation). Results No significant changes in blood pressure, heart rate, or adverse events including rash were attributed to administration of a 50-mg dose of the intravenous LTG formulation. Conclusion Our results show that LTG base that is complexed with 2-hydroxypropyl-β-cyclodextrin and stable-labeled can be given safely as a tracer replacement dose.

Original languageEnglish (US)
Pages (from-to)390-392
Number of pages3
JournalSeizure
Volume23
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Safety
Epilepsy
Pharmacokinetics
Cyclodextrins
Exanthema
Biological Availability
Oral Administration
lamotrigine
Heart Rate
Blood Pressure

Keywords

  • Cyclodextrin
  • Epilepsy
  • Intravenous
  • Lamotrigine
  • Safety

Cite this

Safety of an intravenous formulation of lamotrigine. / Conway, Jeannine M; Birnbaum, Angela K; Leppik, Ilo E; Pennell, Page B.; White, James R.; Rarick, John O.; Remmel, Rory P.

In: Seizure, Vol. 23, No. 5, 01.01.2014, p. 390-392.

Research output: Contribution to journalArticle

Conway, Jeannine M ; Birnbaum, Angela K ; Leppik, Ilo E ; Pennell, Page B. ; White, James R. ; Rarick, John O. ; Remmel, Rory P. / Safety of an intravenous formulation of lamotrigine. In: Seizure. 2014 ; Vol. 23, No. 5. pp. 390-392.
@article{11452e8cf5d54d098f782026df2471d7,
title = "Safety of an intravenous formulation of lamotrigine",
abstract = "Purpose Intravenous (IV) formulations are useful when treating patients where oral administration is not possible and to study certain pharmacokinetic parameters such as bioavailability. We developed a stable-labeled IV formulation of lamotrigine (LTG) for studying pharmacokinetics in epilepsy patients. Methods Stable-labeled IV LTG was given to 20 persons with epilepsy (6 men; 14 women) with a mean age of 34.8 years (SD 11.7). A 50 mg dose of LTG (stable labeled) was given intravenously and replaced 50 mg of the regular morning oral dose of LTG (unlabeled, commercially available formulation). Results No significant changes in blood pressure, heart rate, or adverse events including rash were attributed to administration of a 50-mg dose of the intravenous LTG formulation. Conclusion Our results show that LTG base that is complexed with 2-hydroxypropyl-β-cyclodextrin and stable-labeled can be given safely as a tracer replacement dose.",
keywords = "Cyclodextrin, Epilepsy, Intravenous, Lamotrigine, Safety",
author = "Conway, {Jeannine M} and Birnbaum, {Angela K} and Leppik, {Ilo E} and Pennell, {Page B.} and White, {James R.} and Rarick, {John O.} and Remmel, {Rory P}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.seizure.2014.01.019",
language = "English (US)",
volume = "23",
pages = "390--392",
journal = "Seizure : the journal of the British Epilepsy Association",
issn = "1059-1311",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Safety of an intravenous formulation of lamotrigine

AU - Conway, Jeannine M

AU - Birnbaum, Angela K

AU - Leppik, Ilo E

AU - Pennell, Page B.

AU - White, James R.

AU - Rarick, John O.

AU - Remmel, Rory P

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose Intravenous (IV) formulations are useful when treating patients where oral administration is not possible and to study certain pharmacokinetic parameters such as bioavailability. We developed a stable-labeled IV formulation of lamotrigine (LTG) for studying pharmacokinetics in epilepsy patients. Methods Stable-labeled IV LTG was given to 20 persons with epilepsy (6 men; 14 women) with a mean age of 34.8 years (SD 11.7). A 50 mg dose of LTG (stable labeled) was given intravenously and replaced 50 mg of the regular morning oral dose of LTG (unlabeled, commercially available formulation). Results No significant changes in blood pressure, heart rate, or adverse events including rash were attributed to administration of a 50-mg dose of the intravenous LTG formulation. Conclusion Our results show that LTG base that is complexed with 2-hydroxypropyl-β-cyclodextrin and stable-labeled can be given safely as a tracer replacement dose.

AB - Purpose Intravenous (IV) formulations are useful when treating patients where oral administration is not possible and to study certain pharmacokinetic parameters such as bioavailability. We developed a stable-labeled IV formulation of lamotrigine (LTG) for studying pharmacokinetics in epilepsy patients. Methods Stable-labeled IV LTG was given to 20 persons with epilepsy (6 men; 14 women) with a mean age of 34.8 years (SD 11.7). A 50 mg dose of LTG (stable labeled) was given intravenously and replaced 50 mg of the regular morning oral dose of LTG (unlabeled, commercially available formulation). Results No significant changes in blood pressure, heart rate, or adverse events including rash were attributed to administration of a 50-mg dose of the intravenous LTG formulation. Conclusion Our results show that LTG base that is complexed with 2-hydroxypropyl-β-cyclodextrin and stable-labeled can be given safely as a tracer replacement dose.

KW - Cyclodextrin

KW - Epilepsy

KW - Intravenous

KW - Lamotrigine

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84899633987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899633987&partnerID=8YFLogxK

U2 - 10.1016/j.seizure.2014.01.019

DO - 10.1016/j.seizure.2014.01.019

M3 - Article

C2 - 24560492

AN - SCOPUS:84899633987

VL - 23

SP - 390

EP - 392

JO - Seizure : the journal of the British Epilepsy Association

JF - Seizure : the journal of the British Epilepsy Association

SN - 1059-1311

IS - 5

ER -